Full Text View
Tabular View
No Study Results Posted
Related Studies
Combination Chemotherapy in Treating Women With Stage I Breast Cancer
This study is ongoing, but not recruiting participants.
First Received: March 6, 2003   Last Updated: February 6, 2009   History of Changes
Sponsor: Federation Nationale des Centres de Lutte Contre le Cancer
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00055679
  Purpose

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective in treating early breast cancer.

PURPOSE: Randomized phase III trial to determine the effectiveness of different regimens of combination chemotherapy in treating women who have stage I breast cancer.


Condition Intervention Phase
Breast Cancer
 Drug: cyclophosphamide
Drug: epirubicin hydrochloride
Drug: fluorouracil
Drug: tamoxifen citrate
Procedure: adjuvant therapy
Radiation: radiation therapy
 Phase III

Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control
Official Title: Phase III Randomized Study Of Adjuvant Fluourouracil, Epirubicin And Cyclophosphamide, In Women With Stage I Breast Cancer

Resource links provided by NLM:

Genetics Home Reference related topics: breast cancer
MedlinePlus related topics: Breast Cancer Cancer
Drug Information available for: Cyclophosphamide Fluorouracil Tamoxifen Tamoxifen citrate Epirubicin hydrochloride Epirubicin
U.S. FDA Resources

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Efficacy, in terms of 5-year survival [ Designated as safety issue: No ]
  • Toxicity [ Designated as safety issue: Yes ]
  • Length of survival with biological factors [ Designated as safety issue: No ]
  • Biological factors significant for prognosis and prediction of survival [ Designated as safety issue: No ]
  • Overall survival [ Designated as safety issue: No ]

Estimated Enrollment: 1512
Study Start Date: August 2002
Detailed Description:

OBJECTIVES:

  • Compare the efficacy of 4 vs 6 courses of adjuvant fluorouracil, epirubicin, and cyclophosphamide, in terms of 5-year survival, in women with stage I breast cancer.
  • Compare the toxicity of these regimens in these patients.
  • Determine the correlation of length of survival with biological factors in patients treated with these regimens.
  • Determine biological factors significant for prognosis and prediction of survival of patients treated with these regimens.
  • Determine the overall survival of patients treated with these regimens.

OUTLINE: This is a randomized, open-label, multicenter study. Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive fluorouracil IV, epirubicin IV, and cyclophosphamide IV on day 1. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
  • Arm II: Patients receive the same regimen as in arm I for up to 4 courses. After completion of chemotherapy, patients undergo radiotherapy 5 days a week for 6 weeks. Patients who are estrogen or progesterone receptor positive also receive oral tamoxifen daily for 5 years, beginning after completion of chemotherapy.

Patients are followed every 6 months for 5 years.

PROJECTED ACCRUAL: A total of 1,512 patients (756 per treatment arm) will be accrued for this study within 3 years.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologically confirmed nonmetastatic, unilateral adenocarcinoma of the breast

    • Stage I
    • No clinically or radiologically suspicious metastases
    • No positive sentinel lymph nodes by immunohistochemistry for tumors less than 2 cm

    • No clinically proven positive axillary lymph nodes

      • Tumor cells found on immunohistochemistry only allowed
    • No clinically or radiologically contralateral suspicious lesions
  • No deeply adherent disease
  • No cutaneous invasion
  • No inflammatory disease

  • Complete surgical resection within the past 42 days

    • At least 8 lymph nodes removed
  • Tumor at least 1 cm with no residual disease

  • Presenting with at least 1 of the following factors of a poor prognosis:

    • Tumor greater than 2 cm
    • Hormone receptor negative tumor
    • Grade II or III
    • 35 years old or under

  • Hormone receptor status:

    • Positive or negative

PATIENT CHARACTERISTICS:

Age

  • 18 to 65

Sex

  • Female

Menopausal status

  • Not specified

Performance status

  • WHO 0-1

Life expectancy

  • Not specified

Hematopoietic

  • WBC at least 2,000/mm^3
  • Platelet count at least 100,000/mm^3

Hepatic

  • Bilirubin no greater than 1.25 times upper limit of normal (ULN)
  • AST and ALT no greater than 1.25 times ULN
  • Alkaline phosphatase no greater than 2.5 times ULN
  • No chronic hepatitis B
  • No active hepatitis C

Renal

  • Creatinine no greater than 1.25 times ULN

Pulmonary

  • FEV normal

Other

  • Not pregnant or nursing
  • HIV negative
  • No prior breast cancer or other malignancy
  • No familial, social, or geographical reason that would preclude study participation

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • Not specified

Chemotherapy

  • No prior chemotherapy

Endocrine therapy

  • No prior anticancer hormone therapy

Radiotherapy

  • No prior radiotherapy

Surgery

  • See Disease Characteristics
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00055679

  Show 72 Study Locations
Sponsors and Collaborators
Federation Nationale des Centres de Lutte Contre le Cancer
Investigators
Study Chair: Pierre Kerbrat, MD, PhD Centre Eugene Marquis
  More Information

Additional Information:
Clinical trial summary from the National Cancer Institute's PDQ® database  This link exits the ClinicalTrials.gov site

No publications provided

Study ID Numbers: CDR0000270763, FRE-FNCLCC-PACS-05/0106, EU-20239
Study First Received: March 6, 2003
Last Updated: February 6, 2009
ClinicalTrials.gov Identifier: NCT00055679     History of Changes
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
stage I breast cancer

Additional relevant MeSH terms:
Antimetabolites
Antimetabolites, Antineoplastic
Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Hormone Antagonists
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists
Bone Density Conservation Agents
Cyclophosphamide
Selective Estrogen Receptor Modulators
Antibiotics, Antineoplastic
Estrogen Receptor Modulators
Neoplasms by Site
Therapeutic Uses
 Alkylating Agents
Breast Diseases
Estrogen Antagonists
Skin Diseases
Antineoplastic Agents, Hormonal
Adjuvants, Immunologic
Breast Neoplasms
Tamoxifen
Epirubicin
Immunosuppressive Agents
Pharmacologic Actions
Neoplasms
Fluorouracil
Myeloablative Agonists
Antineoplastic Agents, Alkylating

ClinicalTrials.gov processed this record on November 30, 2009



Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services